Janssen Builds A Pulmonary Pipeline: An Interview With Sue Dillon
Executive Summary
Citing high unmet medical need and significant commercial opportunity, Janssen Research & Development has dived into pulmonary therapeutics. TA head of immunology Sue Dillon discusses the rationale, the indications and the therapeutic approaches the company is taking.
You may also be interested in...
With Remicade Biosimilar On The Rise, J&J Adds Astellas’ JAK2 To Pipeline
The unknowns of JAK inhibitors still offer substantial promise, and Pfizer will likely be the first test subject in the RA space.
In Deals With Respivert And Orexo, J&J's Respiratory Push Gets Going
J&J acquired respiratory drug discovery firm Respivert and licensed two respiratory preclinical research programs from Orexo.
Mesoblast’s Late-Stage Pipeline Could Be Game Changing: Are Investors Paying Attention?
Mesenchymal cell specialist Mesoblast came back from a near-death experience in 2016 when Teva returned a key asset. But recent success in a Phase III trial in acute GVHD has brought it some attention. Now it needs to repeat the achievement in advanced heart failure and find a partner for its burgeoning pipeline.